Reports preliminary Q4 Niktimvo revenue of $56M
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax, WODA collaborate to launch program to expand access to Revuforj
- Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
- Promising Growth Prospects for Syndax Pharmaceuticals: Buy Rating Affirmed by Analyst
- Promising Potential of Syndax Pharmaceuticals’ Revuforj in AML Treatment Drives Buy Rating
- Syndax price target raised to $35 from $22 at Barclays